Grandfield & Dodd LLC Buys Shares of 210,330 Smith & Nephew SNATS, Inc. $SNN

Grandfield & Dodd LLC bought a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 210,330 shares of the medical equipment provider’s stock, valued at approximately $13,192,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada boosted its position in shares of Smith & Nephew SNATS by 16.7% in the first quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock valued at $9,657,000 after acquiring an additional 48,784 shares during the period. Goldman Sachs Group Inc. increased its stake in Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after acquiring an additional 583,809 shares during the period. Focus Partners Wealth raised its holdings in shares of Smith & Nephew SNATS by 59.8% in the 1st quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock worth $552,000 after buying an additional 7,277 shares in the last quarter. Cetera Investment Advisers raised its stake in Smith & Nephew SNATS by 5.9% during the second quarter. Cetera Investment Advisers now owns 17,731 shares of the medical equipment provider’s stock worth $543,000 after acquiring an additional 983 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in Smith & Nephew SNATS by 219.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,261 shares of the medical equipment provider’s stock valued at $161,000 after purchasing an additional 3,613 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Performance

Smith & Nephew SNATS stock opened at $29.69 on Tuesday. The business’s 50-day moving average price is $30.44 and its two-hundred day moving average price is $31.98. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a 12-month low of $28.56 and a 12-month high of $38.79.

Smith & Nephew SNATS Announces Dividend

The company also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a dividend yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on SNN shares. Zacks Research lowered shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Kepler Capital Markets lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Barclays downgraded Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a report on Wednesday, August 5th. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Finally, Canaccord Genuity Group lowered their price target on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research report on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $30.93.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.